Top

International Journal of Clinical Oncology

Published in:

01-04-2014 | Original Article

Amino acid profile index for early detection of endometrial cancer: verification as a novel diagnostic marker

Authors: Yutaka Ihata, Etsuko Miyagi, Reiko Numazaki, Takahiko Muramatsu, Akira Imaizumi, Hiroshi Yamamoto, Minoru Yamakado, Naoyuki Okamoto, Fumiki Hirahara

Published in: International Journal of Clinical Oncology | Issue 2/2014

Abstract

Background

Plasma amino acid profiles (PAAPs) vary in individual cancer patients, and it has been suggested that they may be useful for early detection of several types of cancer. We evaluated the diagnostic performance of a profile index for endometrial cancer composed of multiple plasma amino acids as a novel biomarker and compared its diagnostic performance with that of CA125.

Methods

Plasma amino acid levels of 80 patients with endometrial cancer, 122 with benign gynecological diseases, and 240 age- and body mass index-matched control subjects were measured using liquid chromatography and mass spectrometry. After univariate analysis, we applied a multiplex model based on the PAAP multivariate analysis to distinguish patients with endometrial cancer from control subjects. We compared the diagnostic performance of the multiple PAAP index (API) with that of CA125.

Results

The levels of several plasma amino acids were significantly different in patients with endometrial cancer. The area under the receiver operating characteristic curves (AUC) used to distinguish endometrial cancer patients from control subjects was 0.94. The AUC for API was significantly larger than that for CA125 (P = 0.0068). For the same specificity of 98.3 %, API showed a significantly higher sensitivity (60.0 %, 95 % CI, 43.3–75.1) than that of CA125 (22.5 %, 95 % CI, 10.1–38.5). In stage I cases, API showed significantly higher positivity than that of CA125 (P = 0.0002).

Conclusions

The sensitivity and disease specificity of API for early-stage detection of endometrial cancer was superior to CA125. This novel plasma biomarker has the potential to become a diagnostic and screening marker for endometrial cancer.

Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249PubMedCrossRef

Gynecologic Cancer Committee (2009) Annual report of gynecologic cancer (in Japanese). Acta Obstet Gynaecol Jpn 61:2159–2197

Bast RC Jr, Feeney M, Lazarus H et al (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331–1337PubMedCentralPubMedCrossRef

Niloff JM, Klug TL, Schaetzl E et al (1984) Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 148:1057–1058PubMedCrossRef

Sood AK, Buller RE, Burger RA et al (1997) Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol 90:441–447PubMedCrossRef

Dotters DJ (2000) Preoperative CA 125 in endometrial cancer: is it useful? Am J Obstet Gynecol 182:1328–1334PubMedCrossRef

Fioretti P, Gadducci A, Ferdeghini M et al (1988) Preoperative evaluation of CA 125 and CA 19–9 serum levels in patients with ovarian masses. Eur J Gynaecol Oncol 9:291–294PubMed

Goksedef BP, Gorgen H, Baran SY et al (2011) Preoperative serum CA 125 level as a predictor for metastasis and survival in endometrioid endometrial cancer. J Obstet Gynaecol Can 33:844–850PubMed

Yoshida H, Mizukoshi T, Hirayama K et al (2007) Comprehensive analytical method for the determination of hydrophilic metabolites by high-performance liquid chromatography and mass spectrometry. J Agric Food Chem 55:551–560PubMedCrossRef

10.

Lee K, Hwang D, Yokoyama T et al (2004) Identification of optimal classification functions for biological sample and state discrimination from metabolic profiling data. Bioinformatics 20:959–969PubMedCrossRef

11.

Norton JA, Gorschboth CM, Wesley RA et al (1985) Fasting plasma amino acid levels in cancer patients. Cancer (Phila) 56:1181–1186CrossRef

12.

Naini AB, Dickerson JW, Brown MM (1988) Preoperative and postoperative levels of plasma protein and amino acid in esophageal and lung cancer patients. Cancer (Phila) 62:355–360CrossRef

13.

Cascino A, Muscaritoli M, Cangiano C et al (1995) Plasma amino acid imbalance in patients with lung and breast cancer. Anticancer Res 15:507–510PubMed

14.

Kubota A, Meguid MM, Hitch DC (1992) Amino acid profiles correlate diagnostically with organ site in three kinds of malignant tumors. Cancer (Phila) 69:2343–2348CrossRef

15.

Okamoto N, Miyagi Y, Chiba A et al (2009) Diagnostic modeling with differences in plasma amino acid profiles between non-cachectic colorectal/breast cancer patients and healthy individuals. Int J Med Med Sci 1:1–8

16.

Peduzzi P, Concato J, Kemper E et al (1996) A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 49:1373–1379PubMedCrossRef

17.

R Development Core Team (2009) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna

18.

Proenza AM, Oliver J, Palou A et al (2003) Breast and lung cancer are associated with a decrease in blood cell amino acid content. J Nutr Biochem 14:133–138PubMedCrossRef

19.

Pisters PW, Pearlstone DB (1993) Protein and amino acid metabolism in cancer cachexia: investigative techniques and therapeutic interventions. Crit Rev Clin Lab Sci 30:223–272PubMedCrossRef

20.

Lai HS, Lee JC, Lee PH et al (2005) Plasma free amino acid profile in cancer patients. Semin Cancer Biol 15:267–276PubMedCrossRef

21.

Maeda J, Higashiyama M, Imaizumi A et al (2010) Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC Cancer 10:690PubMedCentralPubMedCrossRef

22.

Uyttenhove C, Pilotte L, Theate I et al (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269–1274PubMedCrossRef

23.

Mellor AL, Munn DH (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4:762–774PubMedCrossRef

24.

Suzuki Y, Suda T, Furuhashi K et al (2010) Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 67:361–365PubMedCrossRef

25.

Vissers YL, Dejong CH, Luiking YC et al (2005) Plasma arginine concentrations are reduced in cancer patients: evidence for arginine deficiency? Am J Clin Nutr 81:1142–1146PubMed

26.

Deligdisch L, Holinka CF (1987) Endometrial carcinoma: two diseases? Cancer Detect Prev 10:237–246PubMed

27.

Opolskiene G, Sladkevicius P, Valentin L (2011) Prediction of endometrial malignancy in women with postmenopausal bleeding and sonographic endometrial thickness ≥4.5 mm. Ultrasound Obstet Gynecol 37:232–240PubMedCrossRef

Title: Amino acid profile index for early detection of endometrial cancer: verification as a novel diagnostic marker
Authors: Yutaka Ihata
Etsuko Miyagi
Reiko Numazaki
Takahiko Muramatsu
Akira Imaizumi
Hiroshi Yamamoto
Minoru Yamakado
Naoyuki Okamoto
Fumiki Hirahara
Publication date: 01-04-2014
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 2/2014
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-013-0565-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2014

Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration

A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix

A comparative study of clinicopathological significance, FGFBP1, and WISP-2 expression between squamous cell/adenosquamous carcinomas and adenocarcinoma of the gallbladder

Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer

Clinicopathologic characteristics and survival of male breast cancer

Is biomarker research advancing in the era of personalized medicine for head and neck cancer?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer